Ebola outbreak surpasses 10,000 cases as international concerns grow
The Ebola outbreak centred in the Democratic Republic of the Congo (DRC) has surpassed 10,000 confirmed infections, becoming the country's deadliest Ebola crisis and the second-largest outbreak recorded globally, according to health authorities.
Data from the US Centers for Disease Control and Prevention (CDC), covering the period up to October 28, 2026, recorded 10,305 confirmed infections and 4,996 deaths across affected countries.
The DRC accounted for 10,274 cases and 4,992 deaths, while additional infections were reported in Uganda, Kenya, Nigeria and France.
The outbreak involves the Bundibugyo strain of Ebola, a rare variant for which no licensed vaccine or specific approved treatment is currently available.
The scale of the outbreak and reports of infections beyond the DRC have intensified concerns about international preparedness and the ability of health systems to contain further transmission.
Rare strain complicates response
Unlike the more widely studied Zaire strain, Bundibugyo presents additional challenges because existing Ebola vaccines are not approved to protect against it.
First identified in Uganda in 2007, the strain has been associated with fatality rates of between 30% and 50% in previous outbreaks.
Researchers are working to develop an effective vaccine, with clinical trial findings expected within three to six months, according to Türkiye Today.
The disease initially produces flu-like symptoms, including fever, headaches and muscle pain. In more severe cases, patients can develop vomiting, diarrhoea, internal bleeding and organ failure.
Incubation period raises cross-border concerns
One of the main challenges facing health authorities is the virus's incubation period, which can extend to 21 days.
This means infected individuals may cross international borders before developing symptoms, complicating efforts to identify and isolate cases.
Cambridge University virus genomics specialist Charlotte Houldcroft said the incubation period generally lasts between eight and 10 days but can extend considerably longer.
However, Ebola does not spread through the air in the same way as COVID-19. Transmission primarily occurs through direct contact with the blood or other bodily fluids of infected individuals.
The risk of transmission increases as the disease progresses and patients become more severely ill.
Cases identified outside the DRC have reinforced concerns about international spread, although health authorities have also reported recoveries among patients treated in Europe.
Testing failures delayed detection
The outbreak was officially declared on May 15, nearly three weeks after a healthcare worker in Bunia died on April 24 following fever, vomiting and severe bleeding.
Initial laboratory tests returned negative results because the testing methods were designed to detect the Zaire strain rather than Bundibugyo.
Healthcare workers initially suspected other illnesses, including malaria and salmonella infection.
As severe bleeding continued among patients, samples were sent for additional laboratory analysis, which eventually identified the Bundibugyo strain.
Investigators believe the virus may have been circulating as early as February in the area surrounding Mongbwalu, a mining town in northeastern Congo.
The delayed identification has raised concerns about diagnostic capacity and the ability of healthcare systems to recognise less common Ebola variants.
WHO and African health authorities urge stronger preparedness
The World Health Organization declared the outbreak a Public Health Emergency of International Concern in May, highlighting the potential for further international transmission and the need for a coordinated response.
Africa Centres for Disease Control and Prevention Director-General Jean Kaseya warned countries against underestimating the threat, drawing comparisons with the early stages of the COVID-19 pandemic.
"Unless appropriate measures are taken, no country is safe," Kaseya warned.
Health authorities are calling for stronger disease surveillance, early diagnosis, effective patient isolation and improved healthcare capacity to prevent further spread.
With thousands of confirmed infections and deaths already recorded, the outbreak presents a major challenge for public health systems, particularly in regions with limited medical resources and difficulties accessing remote communities.
The absence of an approved vaccine against the Bundibugyo strain adds further pressure to containment efforts, while international authorities continue to monitor the possibility of additional cross-border infections.
Source: Türkiye Today, citing US Centers for Disease Control and Prevention data and statements from international health authorities.
